當(dāng)前位置：首頁(yè) SCI期刊 SCIE期刊醫(yī)學(xué) 中科院3區(qū) JCRQ2 期刊介紹(非官網(wǎng))

Expert Review Of Clinical ImmunologySCIE

國(guó)際簡(jiǎn)稱：EXPERT REV CLIN IMMU 參考譯名：臨床免疫學(xué)專家評(píng)論

中科院分區(qū)
3區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q2

基本信息：: ISSN：1744-666X; E-ISSN：1744-8409; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：UNITED STATES; 出版商：Taylor and Francis Ltd.; 出版語(yǔ)言：English; 出版周期：Bimonthly; 出版年份：2005; 研究方向：IMMUNOLOGY

評(píng)價(jià)信息：: 影響因子：3.9; H-index：42; CiteScore指數(shù)：7.6; SJR指數(shù)：1.208; SNIP指數(shù)：1.123

發(fā)文數(shù)據(jù)：: Gold OA文章占比：15.07%; 研究類文章占比：32.33%; 年發(fā)文量：133; 自引率：0.0227...; 開源占比：0.0943; 出版撤稿占比：0; 出版國(guó)人文章占比：0.05; OA被引用占比：0.0481...

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問(wèn)題

英文簡(jiǎn)介Expert Review Of Clinical Immunology期刊介紹

Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology.

Articles focus on the following key areas:

? Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines

? Performance and benefits of newly approved therapeutic agents

? New diagnostic approaches

? Screening and patient stratification

? Pharmacoeconomic studies

? New therapeutic indications for existing therapies

? Adverse effects, occurrence and reduction

? Prospects for medicines in late-stage trials approaching regulatory approval

? Novel treatment strategies

? Epidemiological studies

? Commentary and comparison of treatment guidelines

Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.

期刊簡(jiǎn)介Expert Review Of Clinical Immunology期刊介紹

《Expert Review Of Clinical Immunology》自2005出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：較慢,6-12周
醫(yī)學(xué)
IMMUNOLOGY
SCIE
中科院3區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Expert Review Of Clinical Immunology Cite Score數(shù)據(jù)

CiteScore：7.6
SJR：1.208
SNIP：1.123

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Immunology and Allergy	Q2	73 / 233	68%
大類：Medicine 小類：Immunology	Q2	87 / 236	63%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Expert Review Of Clinical Immunology 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：是 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	3區(qū)	IMMUNOLOGY 免疫學(xué)	3區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Expert Review Of Clinical Immunology JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q2	79 / 181	56.6%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q3	123 / 181	32.32%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA95
Italy78
England39
France27
CHINA MAINLAND26
Canada25
GERMANY (FED REP GER)24
Spain23
Netherlands20
Iran13

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients
Author: Sun, Yu-Qian; Ma, Rui; Huang, Xiao-Jun

Journal: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2023; Vol. 19, Issue 2, pp. 227-235. DOI: 10.1080/1744666X.2023.2161510
2、Innovative treatments for severe uncontrolled chronic rhinosinusitis with nasal polyps
Author: Huang, Yanran; Zhang, Nan; Bachert, Claus

Journal: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/1744666X.2023.2206120
3、Machine learning method for the cellular phenotyping of nasal polyps from multicentre tissue scans
Author: Ding, Jing; Yue, Changli; Wang, Chengshuo; Liu, Wei; Zhang, Libo; Chen, Bo; Shen, Shen; Piao, Yingshi; Zhang, Luo

Journal: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/1744666X.2023.2207824
4、The interaction between innate immunity and oral microbiota in oral diseases
Author: He, Hongzhi; Hao, Yu; Fan, Yu; Li, Bolei; Cheng, Lei

Journal: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2023; Vol. 19, Issue 4, pp. 405-415. DOI: 10.1080/1744666X.2023.2182291
5、Combination strategies for lupus nephritis: facts and controversies
Author: Mok, Chi Chiu

Journal: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2023; Vol. 19, Issue 5, pp. 527-536. DOI: 10.1080/1744666X.2023.2192927
6、Novel insights into central compartment atopic disease-a literature review
Author: Kong, Weifeng; Wu, Qingwu; Zhang, He; Zhang, Yana; Yang, Qintai

Journal: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/1744666X.2023.2192480
7、An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations
Author: Xu, Jia-Ming; Wang, Hai-Meng; Jin, Hong-Zhong

Journal: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2023; Vol. 19, Issue 5, pp. 499-516. DOI: 10.1080/1744666X.2023.2185775
8、The immunomodulatory role of interleukin-35 in fibrotic diseases.
Author: Luo M^1,^2,³, Peng H^1,^2,³, Chen P^1,^2,³, Zhou Y⁴.

Journal: Expert Rev Clin Immunol. 2019 Apr;15(4):431-439. doi: 10.1080/1744666X.2019.1564041. Epub 2019 Jan 11.